Models and estimation methods for clinical HIV-1 data

Journal of Computational and Applied Mathematics

Volumn 184, Issue 1, 2005, Pages 275-300

  Verotta, Davide ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Bayesian; Hierarchical model; MAP; MCMC; Mixed effect

Indexed keywords

APPROXIMATION THEORY; DRUG THERAPY; ESTIMATION; IMMUNOLOGY; MARKOV PROCESSES; MATHEMATICAL MODELS; MONTE CARLO METHODS; STATISTICAL METHODS;

ADHERENCE; BAYESIAN ESTIMATION METHODS; HIERARCHICAL MODEL; HUMAN IMMUNODEFICIENCY VIRUS (HIV); MARKOV CHAIN MONTE CARLO (MCMC); MAXIMUM POSTERIOR APPROXIMATIONS (MAP); MIXED EFFECT;

VIRUSES;

EID: 23344442813     PISSN: 03770427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cam.2004.08.017     Document Type: Article

References (44)

1. H. Akaike A new look at the statistical model identification problem IEEE Trans. Automat. Contr. 19 1974 716-723
2. D.R. Bangsberg F.M. Hecht et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population Aids 14 4 2000 357-366
3. D.M. Bates D.G. Watts Nonlinear Regression Analysis and its Applications 1988 Wiley New York
4. S. Beal, L.B. Sheiner, NONMEM Users Guides, NONMEM PROJECT GROUP, University of California San Francisco, 1998.
5. S. Bonhoeffer J.M. Coffin et al. Human immunodeficiency virus drug therapy and virus load J. Virol. 71 1997 3275-3278
6. J.L. Casado R. Sabido et al. Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients Antivir. Ther. 4 3 1999 157-161
7. T.W. Chun L. Carruth et al Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection Nature 387 1997 183-188
8. T.W. Chun K. Chadwick et al. Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI J. Virol. 71 6 1997 4436-4444
9. C. Cobelli A. Lepschy et al., Identifiability of compartmental systems and related structural properties Math. Biosci. 44 1979 1-18
10. M. Davidian D.M. Giltinan Nonlinear Models for Repeated Measurement Data 1995 Chapman & Hall New York, NY
11. N. Draper H. Smith Applied Regression Analysis second ed. 1981 Wiley New York
12. B. Efron, D. Feldman, Compliance as an explanatory variable in clinical trials, J. Amer. Statist. Assoc. 86, 9-17.
13. N.M. Ferguson F. DeWolf et al. Proc. Nat. Acad. Sci. (USA) 96 1999 15167-15172
14. D. Gamerman Markov Chain Monte Carlo: Stochastic Simulation for Bayesian Inference 1995 Chapman & Hall New York
15. A.E. Gelfand A.F.M. Smith Sampling-based approaches to calculating marginal densities J. Amer. Statist. Assoc. 85 1990 398-409
16. A.E. Gelfand A.F.M. Smith Bayesian statistics without tears: A sampling resampling perspective Amer. Statist. 46 1992 84-88
17. A. Gelman F. Bois et al. Physiological pharmacokinetic analysis using population modeling and informative prior distributions J. Amer. Statist. Assoc. 91 1996 1400-1412
18. S. Geman D. Geman et al. IEEE Trans. Pattern Anal. Mach. Intell. 6 1984 721-741
19. A.L. Gifford J.E. Bormann et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens J. Acquir. Immune Defic. Syndr. 23 5 2000 386-395
20. W.R. Gilks S. Richardson et al. Markov Chain Monte Carlo in Practice 1995 Chapman & Hall New York
21. R.M. Gulick J.W. Mellors et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy N. Engl. J. Med. 337 11 1997 734-739
22. D.W. Haas W.J. Fessel et al Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: A randomized, double-blind, placebo-controlled trial J. Infect. Dis. 183 3 2001 392-400
23. E.J. Hannan Rational transfer function approximation Statist. Sci. 2 1987 1029-1054
24. R.H. Haubrich S.J. Little et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group Aids 13 9 1999 1099-1107
25. Y. Huang S.L. Rosenkranz et al. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity Math. Biosci. 184 2 2003 165-186
26. J.J. Jacquez Parameter estimation: Local identifiability of parameters Amer. J. Physiol. 258 1990 E727-E736
27. J.J. Jacquez P. Greif Numerical parameter identifiability and estimability: Integrating identifiability, estimability, and optimal sampling design Math. Biosci. 77 1985 201-227
28. D. Katz S.P. Azen et al. Bayesian approach to the analysis of nonlinear models: Implementation and evaluation Biometrics 37 1981 137-142
29. L. Labbe, D. Verotta, A non-linear mixed effect dynamic model incorporating compliance to treatment to describe long-term therapy outcome in HIV-patients, 2005, submitted.
30. M.J. Lindstrom D.M. Bates Newton-Raphson and EM algorithms for linear mixed effects models for repeated measured data J. Amer. Statist. Assoc. 83 1988 1014-1022
31. J.W. Mandema D. Verotta et al. Building population pharmacokinetic-pharmacodynamic models J. Pharmacokin. Biopharm 20 1992 511-528
32. M.A. Nowak S. Bonhoeffer et al. Anti-viral drug treatment: Dynamics of resistance in free virus and infected cell population J. Theor. Biol. 184 1997 203-217
33. K. Park D.Z. D'Argenio Uncertain pharmacokinetic/pharmacodynamics systems; design estimation and control Control Eng. Practice 5 1997 1707-1716
34. A.S. Perelson P. Essunger et al. Decay characteristics of HIV-1-infected compartments during combination therapy Nature 387 6629 1997 188-191
35. A.S. Perelson A.U. Neumann et al. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time Science 271 1996 1582-1587
36. F. Schaedeli D. Verotta Mixed effect models characterizing the non-linear dynamics of viral load during long-term anti-HIV-1 therapy Proceedings 14th International Workshop on Statistical Modeling 1999 Graz Austria
37. A.F.M. Smith J.M. Bernardo Bayesian Theory 1994 Wiley New York
38. L. Tierney J. Kadane Accurate approximations for posterior moments and marginal densities J. Amer. Statist. Assoc. 81 1986 82-86
39. I.F. Troconiz L.B. Sheiner et al. Semiparametric models for drug interactions J. Appl. Physiol. 76 1994 2224-2233
40. J. Urquhart E. De Klerk Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens Statist. Med. 17 3 1998 251-267
41. D. Verotta F. Schaedeli Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials Math. Biosci. 176 2002 163-183
42. D. Verotta L.B. Sheiner A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data J. Pharmacokin. Biopharm. 23 1995 1-4
43. J. Wakefield J. Bennett The Bayesian modeling of covariates for population pharmacokinetic models J. Amer. Statist. Assoc. 91 1996 917-927
44. J.C. Wakefield A. Racine-Poon An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation Statist. Med. 14 1995 971-986